Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORPHEUS: INCMGA00012 in Advanced Penile Squamous Cell Carcinoma
2019-001172-11Phase 2Active
- Sponsor
- MEDSIR
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab in penile squamous cell carcinoma (PSCC), sponsored by MEDSIR. Primary endpoint: Objective response rate (ORR). Started Jan 2020; status: active.
02
Drugs
retifanlimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2019-001172-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001172-11.